Drug-related bullous fixed pigmented erythema related to the use of ivermectin in a patient with SARS-Cov2 pneumonia: Case Report
Background: Bullous fixed pigmented erythema is a potentially serious form of toxicoderma. It is characterized by the appearance of cutaneous and / or mucosal lesions, single or multiple, which can appear in any area, after the administration of a drug or other substance. A 73-year-old man is presen...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | Perú |
| Institución: | Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Repositorio: | Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo |
| Idioma: | español |
| OAI Identifier: | oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/1280 |
| Acceso en línea: | https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/1280 |
| Access Level: | acceso abierto |
| Palabra clave: | Eritema fijo pigmentado ampolloso toxicodermia eritema pigmentario medicamentoso Bullous pigmented fixed erythema toxicoderma drug erythema pigmentation |
| Sumario: | Background: Bullous fixed pigmented erythema is a potentially serious form of toxicoderma. It is characterized by the appearance of cutaneous and / or mucosal lesions, single or multiple, which can appear in any area, after the administration of a drug or other substance. A 73-year-old man is presented with a diagnosis of bullous fixed pigmented erythema secondary to the ingestion of ivermectin. It is necessary for the physician to recognize the adverse effects of self-medication with ivermectin against SARS CoV-2, to make an early diagnosis and initiate timely treatment. |
|---|